Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07195682) titled 'A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)' on Sept. 25.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Bristol-Myers Squibb
Condition:
Renal Cell Carcinoma
Intervention:
Drug: BMS-986506
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: December 15, 2025
Target Sample Size: 125
Countries of Recruitment:
United States
Canada
France
Spain
Canada
France
Spain
United States
To k...